Gunnar Knobloch

Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes.Screening and cellular platforms are yielding first-in-class inhibitors to directly target the key vulnerability found in genetically defined tumors.It is founded in 2019 and is based in Martinsried, Bavaria.